Free Trial

Viking Therapeutics (VKTX) Competitors

Viking Therapeutics logo
$32.91 -0.29 (-0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$32.74 -0.17 (-0.53%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VKTX vs. MDGL, LLY, GMAB, RDY, MRNA, QGEN, VTRS, ASND, VRNA, and BBIO

Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector.

Viking Therapeutics vs. Its Competitors

Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Viking Therapeutics presently has a consensus target price of $86.92, suggesting a potential upside of 164.12%. Madrigal Pharmaceuticals has a consensus target price of $420.63, suggesting a potential upside of 42.88%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00
Madrigal Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Viking Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.05, suggesting that its stock price is 205% less volatile than the S&P 500.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -123.38%. Viking Therapeutics' return on equity of -19.98% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -19.98% -19.38%
Madrigal Pharmaceuticals -123.38%-50.54%-37.19%

In the previous week, Viking Therapeutics had 31 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 43 mentions for Viking Therapeutics and 12 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.63 beat Viking Therapeutics' score of 0.04 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viking Therapeutics
10 Very Positive mention(s)
6 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Madrigal Pharmaceuticals
6 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Viking Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Viking Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$109.96M-$1.53-21.51
Madrigal Pharmaceuticals$180.13M36.28-$465.89M-$18.05-16.31

Summary

Viking Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VKTX vs. The Competition

MetricViking TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.73B$3.02B$5.70B$9.56B
Dividend YieldN/A2.40%4.71%4.06%
P/E Ratio-21.5121.0028.1919.94
Price / SalesN/A331.85461.9396.03
Price / CashN/A42.5736.3258.72
Price / Book4.658.138.295.77
Net Income-$109.96M-$55.06M$3.25B$259.21M
7 Day Performance2.52%0.88%0.21%-0.80%
1 Month Performance24.10%15.04%8.71%9.81%
1 Year Performance-46.27%2.54%32.76%14.37%

Viking Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VKTX
Viking Therapeutics
4.5377 of 5 stars
$32.91
-0.9%
$86.92
+164.1%
-49.7%$3.73BN/A-21.5120Trending News
Earnings Report
Analyst Revision
Gap Up
MDGL
Madrigal Pharmaceuticals
4.2535 of 5 stars
$330.50
-1.1%
$420.63
+27.3%
+3.4%$7.33B$180.13M-18.2990
LLY
Eli Lilly and Company
4.9797 of 5 stars
$762.72
-1.2%
$1,012.56
+32.8%
+0.4%$722.75B$49.00B62.0547,000Trending News
Analyst Upgrade
Gap Down
GMAB
Genmab A/S
4.0326 of 5 stars
$21.67
-1.0%
$37.80
+74.5%
-18.6%$13.91B$3.12B12.322,682News Coverage
Positive News
Analyst Upgrade
RDY
Dr. Reddy's Laboratories
2.6616 of 5 stars
$14.56
+0.6%
$16.95
+16.4%
-9.5%$12.14B$3.81B22.0227,811Earnings Report
MRNA
Moderna
4.257 of 5 stars
$30.91
-1.1%
$46.61
+50.8%
-72.2%$12.01B$3.24B-3.565,800Upcoming Earnings
QGEN
Qiagen
3.6232 of 5 stars
$48.13
-0.5%
$49.40
+2.7%
+19.4%$10.70B$1.98B120.655,765Positive News
Upcoming Earnings
Analyst Downgrade
VTRS
Viatris
2.6181 of 5 stars
$8.89
+0.1%
$10.40
+17.1%
-23.3%$10.44B$14.74B-2.8132,000
ASND
Ascendis Pharma A/S
3.379 of 5 stars
$168.19
-1.0%
$223.07
+32.6%
+22.7%$10.31B$393.54M-26.851,017News Coverage
Analyst Forecast
VRNA
Verona Pharma PLC American Depositary Share
2.7655 of 5 stars
$104.93
+0.0%
$109.00
+3.9%
+362.3%$8.93B$42.28M-52.4630Positive News
BBIO
BridgeBio Pharma
4.6257 of 5 stars
$45.85
-1.4%
$61.50
+34.1%
+70.9%$8.74B$221.90M-13.03400News Coverage
Upcoming Earnings
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:VKTX) was last updated on 7/29/2025 by MarketBeat.com Staff
From Our Partners